尿激酶与低分子肝素钙联用治疗急性心肌梗死临床效果观察

Clinical effect observation on treating acute myocardial infarction with urokinase and low molecular weight heparin calcium

目的:观察尿激酶与低分子肝素钙联用治疗急性心肌梗死的临床效果。方法:选取2014年4月-2017年4月于我院收治急性心肌梗死患者116例,运用随机数字表法划分为对照组和观察组,对照组采用低分子肝素钙治疗,观察组在对照组的基础上联用尿激酶,比较两组患者治疗效果。结果:观察组治疗总有效率为87.93%显著高于对照组的68.97%(P<0.05);观察组胸痛缓解时间,CK-MB变化时间以及ST段下降超过50%时间均显著低于对照组(P<0.05);观察组于12h内冠状动脉再通率为72.41%显著高于对照组39.66%(P<0.05);观察组心脏事件总发生率为8.62%显著低于对照组27.59%(P<0.05)。结论:尿激酶与低分子肝素钙联用治疗急性心肌梗死治疗效果好,有效降低胸痛缓解时间,减少并发症,具有临床推广意义。

Objective:To observe the clinical effect of urokinase and low molecular weight heparin calcium on acute myocardial infarction.Methods:116cases patients with acute myocardial infarction treated in our hospital were selected and randomly divided into two groups.The control group received low molecular weight heparin calcium treatment while the observation group received urokinase and low molecular weight heparin calcium treatment.The effect in two groups was compared.Results:The total effective rate in the observation group was87.93%,which was significantly higher than68.97%in the control group(P<0.05).The chest pain relief time,CK-MB change time and ST segment decreased by more than50%time in the observation group were significantly lower than those in the control group(P<0.05).The internal coronary artery recanalization rate in12h in the observation group was72.41%,which was significantly higher than39.66%in the control group(P<0.05).The total incidence of cardiac events in the observation group was8.62%,which was significantly lower than27.59%in the control group(P<0.05).Conclusion:Urokinase and low molecular weight heparin calcium showed a good effect on acute myocardial infarction,could effectively reduce chest pain relief time,reduce complications,and was of clinical popularization significance.